560 related articles for article (PubMed ID: 27355533)
1. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
5. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
[TBL] [Abstract][Full Text] [Related]
6. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
7. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
[TBL] [Abstract][Full Text] [Related]
9. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
10. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
11. Midostaurin in Advanced Systemic Mastocytosis.
Chandesris MO; Damaj G; Canioni D; Brouzes C; Lhermitte L; Hanssens K; Frenzel L; Cherquaoui Z; Durieu I; Durupt S; Gyan E; Beyne-Rauzy O; Launay D; Faure C; Hamidou M; Besnard S; Diouf M; Schiffmann A; Niault M; Jeandel PY; Ranta D; Gressin R; Chantepie S; Barete S; Dubreuil P; Bourget P; Lortholary O; Hermine O;
N Engl J Med; 2016 Jun; 374(26):2605-7. PubMed ID: 27355555
[No Abstract] [Full Text] [Related]
12. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
14. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
15. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
Hochhaus A; Baccarani M; Giles FJ; le Coutre PD; Müller MC; Reiter A; Santanastasio H; Leung M; Novick S; Kantarjian HM
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2047-60. PubMed ID: 26002753
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Sly N; Gaspar K
Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Galinsky I; Coleman M; Fechter L
Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
[TBL] [Abstract][Full Text] [Related]
18. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
Lübke J; Schwaab J; Naumann N; Horny HP; Weiß C; Metzgeroth G; Kreil S; Cross NCP; Sotlar K; Fabarius A; Hofmann WK; Valent P; Gotlib J; Jawhar M; Reiter A
J Clin Oncol; 2022 Jun; 40(16):1783-1794. PubMed ID: 35235417
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
Schlenk RF; Kayser S
Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
[TBL] [Abstract][Full Text] [Related]
20. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
